N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy

• Status: Unknown status
• Trial end date: 2012-02-01
• Target enrollment: 0
• Participant gender: All

Summary

In this study we want to investigate the efficacy of N-acetylcysteine (NAC), which is an anti-oxidant, in the prevention of cisplatin-induced neural toxicity, in patients treated for lung cancer with chemotherapy containing cisplatin.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rijnstate Hospital
• Treatments: Acetylcysteine; N-monoacetylcystine

Criteria

Inclusion Criteria:

• diagnose is histologically or cytologically proven (NSCLC,SCLC), malignant mesothelioma (histologically)

• at least 4 cycles of cisplatin are planned

• adequate renal function (creatinine clearance as calculated by Cockroft-Gault method > 60 ml/min)

• Karnofsky performance score > 60 %

• written informed consent

• patient must be able to comply with study measurements i.e. hospital visits for EMG and QoL assessments

• age ≥ 18 years

Exclusion Criteria:

• patients with pre-existing neuropathy

• patients not willing to stop earlier prescribed NAC

• patients not willing to stop vitamins E and A above daily advisory dosage

• uncontrolled metastasis in the central or peripheral nervous system